Official Statement, Stock Price Movements, and Public Offering of Common Stock - Research Report on Amgen, Biogen Idec, Express

Official Statement, Stock Price Movements, and Public Offering of Common Stock
   - Research Report on Amgen, Biogen Idec, Express Scripts, Endo, and CSI

PR Newswire

NEW YORK, November 26, 2013

NEW YORK, November 26, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Amgen,
Inc. (NASDAQ: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Express Scripts Holding
Company (NASDAQ: ESRX), Endo Health Solutions Inc. (NASDAQ: ENDP), and
Cardiovascular Systems Inc. (NASDAQ: CSII). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Amgen, Inc. Research Report

On November 21, 2013, Amgen, Inc. (Amgen) published a statement regarding a
misleading note issued by the biotech analyst at Bank of America Merrill
Lynch, after a dinner meeting with Celgene management. According to Amgen, in
its follow up with Celgene, they acknowledged citing anecdotal reports from
high volume multiple myeloma centers of cardiovascular (CV) events with
Kyprolis, a product that Onyx holds global rights to, but also clarified that
Celgene made no representation of the event rates being any different than
what is already included in the Kyprolis label. Amgen informed that the Phase
3 Kyprolis trials are monitored and safety data are reviewed regularly by
independent Data Monitoring Committees (DMCs), and no DMCs have reported any
specific safety concerns and have recommended continuing the Phase 3 studies,
to date. Amgen reported that The Bank of America Merrill Lynch note
incorrectly characterizes confidential information on event rates during the
course of the ASPIRE study, which are not shared with Celgene as part of the
supply agreement. Amgen added that its post-marketing reporting and on-going
clinical data have not revealed any new safety concerns. The Full Research
Report on Amgen, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/e96b_AMGN

Biogen Idec Inc. Research Report

On November 21, 2013, Biogen Idec Inc. (Biogen Idec)'s stock rose 2.56%,
ending the day at $252.43. Over the previous three trading sessions, shares of
Biogen Idec rose 4.63% compared to the Nasdaq Composite which gained 0.51%
during the same period. The Full Research Report on Biogen Idec Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b95b_BIIB

Express Scripts Holding Company Research Report

On November 21, 2013, Express Scripts Holding Company's (Express Scripts)
stock rose 1.08%, ending the day at $65.88. Over the previous three trading
sessions, shares of Express Scripts gained 1.37% compared to the Nasdaq
Composite which gained 0.51% over the same period. The Full Research Report on
Express Scripts Holding Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/91a7_ESRX

Endo Health Solutions Inc. Research Report

On November 19, 2013, Endo Health Solutions Inc. (Endo) announced that the
Company has commenced consent solicitations with respect to proposed
amendments to the indentures governing its senior notes listed, which include
7% Senior Notes due 2019, 7.00% Senior Notes due 2020, and 7¼% Senior Notes
due 2022, subject to the terms and conditions set forth in the Consent
Solicitation Statement, dated November 19, 2013 (the Statement). Endo stated
that it is soliciting consents from holders of record of each series of Notes
as of 5:00 p.m., New York City time, on the day of the release, to certain
proposed amendments to each of the indentures governing the Notes. Endo added
that subject to the terms and conditions set forth in the Statement, it will
pay eligible holders who validly deliver and do not revoke their consents on
or prior to 5:00 p.m. New York City time, on November 27, 2013, as may be
extended by Endo with respect to one or more series of the Notes in accordance
with the Statement, a cash payment equal to $2.50 per $1,000 aggregate
principal amount of each series of Notes consented. The Full Research Report
on Endo Health Solutions Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/059c_ENDP

Cardiovascular Systems Inc. Research Report

On November 20, 2013, Cardiovascular Systems Inc. (CSI) announced the pricing
of an underwritten public offering of approximately 2.6 million shares of
common stock, at a price to the public of $30.00 per share. CSI reported that
it expects the net proceeds from the sale of the shares, after deducting
underwriting discounts and commissions and estimated expenses, of
approximately $73.4 million. Further, CSI informed that all of the shares in
the offering are to be sold by CSI. The Company is expecting the offer to
close on or about November 26, 2013. The Company added that CSI granted the
underwriters a 30-day option to purchase up to an additional 391,304 shares.
The Full Research Report on Cardiovascular Systems Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/11b9_CSII

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.analystscorner.com/

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)